SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
DNA: Bull or Bear?
Discovery Labs: The Next Biotech Winner?
DNA
|
|
|
-15.07%
in
6 days
I think the recent decline in Discovery Labs (DSCO) since the Company announced a minor delay in submitting a complete response to the FDA for an approvable ruling on Surfaxin represents a buying opportunity and bought some shares on Friday at $1.74 per share. Insider buying over the past two months (including a 75,000 share buy from the CEO at $1.87) demonstrates management's confidence in already meeting the FDA's requirements and the plan to submit a complete response to FDA for Surfaxin, which should now occur by about the third ...
|
Cramer on BloggingStocks: Genentech bid confirms the trend
DNA
-22.26%
in
83 days
Filed under: Deals, Market matters, Anheuser-Busch Cos (BUD), Research in Motion (RIMM), Genentech Inc (DNA), Amgen Inc (AMGN), Gilead Sciences (GILD), Stocks to Buy, Cramer on BloggingStocks  TheStreet.com's Jim Cramer says the biotechs look sweet in a bank-led slowdown.
Thank you, New York Times. Remember just a couple of weeks ago, when The New York Times wrote about how Genentech's (NYSE: DNA) (Cramer's Take) Avastin was too expensive and the stock got cracked down to $77? I know Roche did. I bet that was the last draw. The dramatic decline in the dollar plus a sentiment that has spawn...
|
Bullish on DNA ...
DNA
|
|
|
-7.16%
in
92 days
Analysts' Recommendation: Buy 30 Days Ago: Buy Analysts' Target: $83 Analysts' Targets Deutsche Bank Securities $83 Accumulate Thursday, June 19, 2008 RBC Capital Markets $84 Outperform Monday, February 25, 2008 Jefferies & Co. $78 Accumulate Monday, February 25, 2008 Lazard Capital Markets $87 Strong Buy Monday, February 25, 2008 Lehman Brothers $70 Equalweight Monday, February 25, 2008 Friedman, Billings, Ramsey & C $76 Hold Monday, February 25, 2008 UBS Securities $95 Add ...
|
S&P Fair Value :$93.80
DNA
|
|
|
-6.07%
in
98 days
Per the S&P: Although we consider DNA a core biotechnology holding, we see the shares as appropriately valued, given slowing growth trends across the product portfolio.We see recent FDA accelerated Avastin approval in metastatic breast cancer supporting the shares, preserving prior offlabel prescribing, and expect full approval as new studies confirm progression-free survival trends.We remain positive on DNA's long-term pipeline, with 15 new compounds entering clinical study in the first two years of a five-year, 30 new compound goal, and see DNA well positioned to benefit from robust fr...
|
Avastin Vastly Improves Genentech
DNA
-0.19%
in
130 days
The approval of Avastin in metastatic breast cancer opens up a potential billion-dollar opportunity for Genentech, in our view.
|
the world's premier biotechnology company.
DNA
|
|
|
-1.51%
in
180 days
We are reiterating our rating on Genentech at Buy, and
keeping our target price at $86 / share. We remind investors
that we upgraded the name in February based on the
Accelerated Approval of Avastin for 1st-line metastatic
breast cancer. Our EPS forecasts for 2008 through 2012
have been adjusted higher based on expected higher sales
of Avastin going forward. We are also encouraged by the
recent positive data on Rituxan in multiple sclerosis (MS).
Genentech is the world s premier biotechnology company.
The stock has struggled over the past several quarters.
Howe...
|
Genetech Inc. March Calls
DNA
+1.37%
in
233 days
Genetech Inc. (DNA) March options in the 70, 75,
and 80 calls are being purchased with high volume today ahead of a FDA
decision.
|
Fast Money Recap, 4/10/08: Retail Charges Ahead
DNA
+5.19%
in
184 days
Recap of CNBC's Fast Money, Thursday April 10. Click on a stock ticker for more analysis.
<!--more-->
Retail:Wal-Mart (WMT), Costco (COST)Macke noted the retail sector is pushing ahead in spite of bad news and likes WMT and COST.
<!----> Tech: Micrsoft (MSFT), Yahoo (YHOO), Intel (INTC), Cisco (CSCO)
Najarian approved of INTC valuation and would also buy CSCO. Seymour commented on the two companies’ international exposure. Najarian thinks YHOO will slowly rise. Macke says Bill Miller and shareholders are have more power over Yahoo than its management, and he thinks it is time to leave ...
|
Fast Money Recap, 4/10/08: Retail Charges Ahead
DNA
+0.00%
in
0 minute
(closed on 04/11/08)
Recap of CNBC's Fast Money, Thursday April 10. Click on a stock ticker for more analysis.
<!--more-->
Retail:Wal-Mart (WMT), Costco (COST)Macke noted the retail sector is pushing ahead in spite of bad news and likes WMT and COST.
<!----> Tech: Micrsoft (MSFT), Yahoo (YHOO), Intel (INTC), Cisco (CSCO)
Najarian approved of INTC valuation and would also buy CSCO. Seymour commented on the two companies’ international exposure. Najarian thinks YHOO will slowly rise. Macke says Bill Miller and shareholders are have more power over Yahoo than its management, and he thinks it is time to leave ...
|
Global Changes in Agriculture are Driven by R&D
DNA
|
|
|
-6.77%
in
69 days
(closed on 06/12/08)
In 99 and 2000 when I was a student at U.C. Berkeley research staff discussed how any stock with the term Genetics or DNA in its title was skyrocketing. Research is always an area of financial risk, as the supply of ideas can never match the demand for idea driven products. Ideas can change the way business is done and who does it. These guys have survived several crashes in the bio-research field and many ideas in their labs are waiting for a market recovery for action to meet the market demand. This is a hardened business with big upside potential and a moderatel ...
|
DNA - buy below fair value of $74.90
DNA
|
|
|
-0.95%
in
416 days
About
Genentech, Inc. (Genentech) is a biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for unmet medical needs. The Company manufactures and commercializes multiple biotechnology products, and receives royalties from companies that are licensed to market products based on its technology. Genentech commercializes various products in the United States, including Avastin, Rituxan, Herceptin, Lucentis, Xolair, Tarceva, Nutropin, Activase, TNKase, Cathflo Activase, Pulmozyme and Raptiva. The Company’s licensed products include Trastuzumab...
|
Buy Genentech (DNA) and get 15% compounded rate of return for 5 years.
DNA
|
|
|
-4.72%
in
488 days
The biotech sector hasn't been doing so well but Genentech (DNA), the world's second largest biotechnology company, should outperform over the long term. Genentech markets -Avastin for treating metastatic cancer of the colon or rectum and metastatic non-squamous non-small cell lung cancer, -Rituxan to treat B-cell non-Hodgkins lymphoma -Herceptin for treating node-positive breast cancer -
|
Genentech (DNA)
DNA
|
|
|
-10.43%
in
545 days
On February 24, 2007, I wrote up my "Long-term review #5" Agree Realty . ADC was posted on May 16, 2003. The next entry on the blog is dated May 19, 2003, and is about Genentech (DNA). I wrote :
" May 19, 2003 Genentech (DNA)
Overall a lousy day in the market. Genentech (DNA) tops the largest percentage gainers today with news about a new possible treatment for Colon and Rectal Cancer. Advanced colon and rectal cancer has a rather dismal prognosis and we all know people who have succumbed to the disease. Anyhow Genentech has a new drug cal ...
|
Bullish on DNA ...
DNA
|
|
|
-10.24%
in
710 days
Biopharmaceuticals Biopharmaceuticals -- unless the feds begin to position themselve in a way which indicates they'll shorten the lifespan of a biopharmaceuticals patent, companies like Genetech will be great long terms plays, on a sea of other choppy variables. I've watched them for several years and know their inner working.
|
People Bullish on DNA
People Bearish on DNA
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Trader who needs HELP!!
- Im looking for a Stock Pick Website. What are the most important things for me to look for? What makes a good Stock Pick site? What sort of content sho
|
More Resources
|
About Genentech Inc
- Answers.com
